Literature DB >> 10653100

Anterior reconstructive spinal surgery with Zielke instrumentation for metastatic malignancies of the spine.

L H Chen1, W J Chen, C C Niu, C H Shih.   

Abstract

From March 1984 to April 1996, 60 consecutive patients with spinal metastasis underwent palliative surgery by anterior corpectomy and Zielke instrumentation. Their ages ranged from 21 to 76 years (mean 54 years). Thirty-two patients had metastasis to the thoracic spine, 20 to the lumbar spine, and 8 had both thoracic and lumbar metastases. The primary malignancies were lung cancer in 12 patients, colorectal cancer in 10, hepatoma in 9, thyroid cancer in 7, breast cancer in 3, and cancers of the stomach, kidney, nasopharynx, long bones, skin, and cervix in 1 patient each. A primary carcinoma was never identified in 13 patients. In the present series, 4 patients died within 1 month, and 56 patients were followed-up. All maintained spinal stability postoperatively. Forty of 52 patients with severe pain obtained significant symptomatic relief for 3 months or more, and 33 of the 46 paralyzed patients gained neural improvement. Sphincter dysfunction became better in 10 patients, and none became worse. We conclude that anterior corpectomy to decompress neural encroachment with instrumental reconstruction to stabilize the collapsed spine is a good adjunctive treatment in these highly selected patients.

Entities:  

Mesh:

Year:  2000        PMID: 10653100     DOI: 10.1007/pl00021238

Source DB:  PubMed          Journal:  Arch Orthop Trauma Surg        ISSN: 0936-8051            Impact factor:   3.067


  9 in total

1.  Surgical treatment strategies and outcome in patients with breast cancer metastatic to the spine: a review of 87 patients.

Authors:  Joseph A Shehadi; Daniel M Sciubba; Ian Suk; Dima Suki; Marcos V C Maldaun; Ian E McCutcheon; Remi Nader; Richard Theriault; Laurence D Rhines; Ziya L Gokaslan
Journal:  Eur Spine J       Date:  2007-04-04       Impact factor: 3.134

Review 2.  Emerging techniques in the minimally invasive treatment and management of thoracic spine tumors.

Authors:  Zachary A Smith; Isaac Yang; Alessandra Gorgulho; Dan Raphael; Antonio A F De Salles; Larry T Khoo
Journal:  J Neurooncol       Date:  2011-11-18       Impact factor: 4.130

3.  Surgery for metastatic epidural spinal cord compression in thoracic spine, anterior or posterior approach?

Authors:  Jen-Chung Liao; Wen-Jer Chen; Lih-Hui Chen
Journal:  Biomed J       Date:  2021-03-24       Impact factor: 7.892

Review 4.  A systematic review of MIS and open decompression surgery for spinal metastases in the last two decades.

Authors:  Bhoresh Dhamija; Dheeraj Batheja; Birender Singh Balain
Journal:  J Clin Orthop Trauma       Date:  2021-09-25

5.  Distractible vertebral body replacement in patients with malignant vertebral destruction or osteoporotic burst fractures.

Authors:  Torsten Kluba; Johannes P Giehl
Journal:  Int Orthop       Date:  2004-04       Impact factor: 3.075

6.  Positive and negative prognostic variables for patients undergoing spine surgery for metastatic breast disease.

Authors:  Daniel M Sciubba; Ziya L Gokaslan; Ian Suk; Dima Suki; Marcos V C Maldaun; Ian E McCutcheon; Remi Nader; Richard Theriault; Laurence D Rhines; Joseph A Shehadi
Journal:  Eur Spine J       Date:  2007-05-08       Impact factor: 3.134

7.  [Surgical complications after metastatic infiltration of the spine].

Authors:  C Hessler; F Raimund; J Regelsberger; J Madert; A Ekkernkamp; C Eggers
Journal:  Chirurg       Date:  2007-10       Impact factor: 0.955

8.  Outcomes after surgery for spinal metastasis of colorectal origin: case series.

Authors:  Matthew R Leach; Darryl Lau; Frank La Marca; Paul Park
Journal:  Asian Spine J       Date:  2014-06-09

9.  Impact of decompressive laminectomy on the functional outcome of patients with metastatic spinal cord compression and neurological impairment.

Authors:  Alexander Younsi; Lennart Riemann; Moritz Scherer; Andreas Unterberg; Klaus Zweckberger
Journal:  Clin Exp Metastasis       Date:  2020-01-20       Impact factor: 5.150

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.